Matinas BioPharma Holdings, Inc.
Income Statement
| Line Item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $3.2M | $33.0K | $158.3K | $89.8K | $119.8K | $149.7K | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $14.5M | $16.7M | $14.6M | $14.4M | $11.2M | $6.8M | $9.0M | $3.9M |
| SG&A Expense | $10.4M | $11.1M | $10.2M | $10.0M | $7.8M | $8.0M | $7.6M | $4.3M |
| Operating Income | $-23.8M | $-24.6M | $-24.7M | $-24.2M | $-18.9M | $-14.6M | $-16.5M | $-8.3M |
| Operating Margin | -2,168.4% | -771.3% | -74,954.5% | -15,288.4% | -21,067.4% | -12,230.9% | -11,024.6% | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-22.9M | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | $506.9K | $400.0K | — |
| Net Income | $-22.9M | $-21.0M | $-23.3M | $-22.4M | $-17.4M | $-14.1M | $-15.5M | $-7.6M |
| Net Margin | -2,093.2% | -658.6% | -70,554.5% | -14,177.0% | -19,343.4% | -11,760.4% | -10,345.9% | — |
| EPS (Basic) | $-5.28 | $-0.10 | $-0.11 | $-0.12 | $-0.13 | $-0.15 | $-0.36 | $-0.21 |
| EPS (Diluted) | $-5.28 | $-0.10 | $-0.11 | $-0.12 | $-0.13 | $-0.15 | $-0.36 | $-0.21 |
| Shares Outstanding (Basic) | 4.3M | 216.8M | 210.2M | 200.1M | 163.2M | 113.3M | 93.4M | 58.2M |
| Shares Outstanding (Diluted) | 4.3M | 216.8M | 210.2M | 200.1M | 163.2M | 113.3M | 93.4M | 58.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |